Workflow
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Core Insights - Coherus BioSciences announced promising clinical data for CHS-114, a selective anti-CCR8 antibody, demonstrating efficacy in combination with toripalimab for treating head and neck squamous cell carcinoma (HNSCC) and gastric cancer [1][2][4] - A confirmed partial response was observed in a heavily pretreated PD-1 refractory patient, indicating potential for overcoming PD-1 resistance [2][13] - The ongoing Phase 1b trial aims to optimize dosing and evaluate safety and efficacy, with results expected in the first half of 2026 [1][8] Company Overview - Coherus BioSciences is focused on developing innovative oncology treatments, including the next-generation PD-1 inhibitor, LOQTORZI (toripalimab), and has a pipeline targeting various cancers [16][17] - The company is advancing CHS-114 in combination with toripalimab in two Phase 1b clinical trials for advanced solid tumors, including HNSCC and gastric cancer [15][17] Clinical Trial Details - The Phase 1b trial evaluated CHS-114 as a monotherapy and in combination with toripalimab in 21 patients, focusing on dose-limiting toxicities and treatment-emergent adverse events [5][12] - Key findings include a significant depletion of CCR8+ Treg cells (52-97%) and an increase in CD8+ T cells, supporting the mechanism of action for CHS-114 [6][13] Future Directions - The company plans to continue exploring CHS-114's potential in various solid tumors, with a strategic focus on HNSCC and gastric cancer [4][8] - Upcoming data presentations are expected to provide further insights into the efficacy and safety of CHS-114 in combination therapies [1][9]